Kyowa Kirin Co., Ltd.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kyowa Kirin Co., Ltd. develops, manufactures, and markets specialty pharmaceuticals worldwide, focusing on biotechnology-driven innovation in oncology, nephrology, immunology, central nervous system disorders, rare diseases, bone and mineral metabolism, and intractable hematologic diseases. The company offers core products including Crysvita, a recombinant fully human monoclonal IgG1 antibody targeting fibroblast growth factor 23 for X-linked hypophosphatemia; POTELIGEO (mogamulizumab-kpkc), a humanized monoclonal antibody against CC chemokine receptor 4 for cutaneous T-cell lymphomas produced via the proprietary POTELLIGENT platform; Nourianz (istradefylline), an adenosine A2A receptor antagonist as adjunctive therapy for Parkinson's disease "off" episodes; and additional therapies such as Grasin, Neurasta, Romiplate in hematology, and Nesp, Regpara, Orkedia in nephrology. Founded on July 1, 1949 and headquartered at Otemachi Financial City Grand Cube in Tokyo's Chiyoda-ku, Kyowa Kirin operates globally with a presence in Japan, the United States, Europe, Asia-Pacific including South Korea, Taiwan, Australia, Singapore, Thailand, Malaysia, Hong Kong, Macau, and the Middle East; it functions as a subsidiary of Kirin Holdings Company, Limited, with approximately 5,669 consolidated employees. Recent developments include a 2024 acquisition of its Korean specialty pharma unit by DKSH Korea, covering sales, marketing, and distribution of key hematology and nephrology products to enhance regional accessibility; strategic partnerships with DKSH Holding and Hong Kong WinHealth Pharma Group for Asia-Pacific optimization of established brands while prioritizing Global 2 Brands like CRYSViTA and POTELIGEO in select markets; and a December 2024 research collaboration with Cimeio Therapeutics, valued at up to $300 million, leveraging Cimeio's Shielded Cell and Immunotherapy platform with Kyowa Kirin's cell therapy expertise for novel treatments in high-unmet-need diseases.
Kyowa Kirin stops development of skin condition treatment
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin (OTCMKTS:KYKOF) Trading Down 4.5% – Time to Sell?
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting